Develops and commercializes a unique technology aimed at detecting early biomarkers in lung medicine. Pexa offer a non-invasive method for sampling biological material from the liquid layer that covers the human's most distal airways, which gives new opportunities for the development of more precise diagnostics and effective drugs.
Impact: Contribute to a better life for patients with respiratory diseases by facilitating the development of faster and more reliable diagnosis, follow-up and treatment.
CEO: Erik Ekbo
GUV Contact: Jan Pilebjer
Location: Sweden, Gothenburg
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 11.04.2023 | Startup Showcase: PExA – A Revolutionary Instrument for Resp... | Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), affect millio... | eustartup.... |